Influence of dietary substances on intestinal drug metabolism and transport

Current Drug Metabolism

Volumn 11, Issue 9, 2010, Pages 778-792

  Won, Christina S ^a   Oberlies, Nicholas H ^b   Paine, Mary F ^a  

^a University of North Carolina   (United States)

^b UNIVERSITY OF NORTH CAROLINA AT GREENSBORO   (United States)

Author keywords

Bioavailability; Drug interaction; Food; Fruit juice; Grapefruit juice; Intestine; Metabolism; Transport

Indexed keywords

ALISKIREN; BUDESONIDE; CALCIUM; CALCIUM CHANNEL BLOCKING AGENT; CELIPROLOL; CYCLOSPORIN; CYTOCHROME P450 3A; DEXTROMETHORPHAN; ENALAPRIL; ESTERASE; FELODIPINE; FEXOFENADINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ITRACONAZOLE; MEVINOLIN; MIDAZOLAM; NILOTINIB; ORGANIC ANION TRANSPORTER 1; OXYCODONE; PRAVASTATIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SERTRALINE; SIMVASTATIN; SULFOTRANSFERASE; SUNITINIB; TACROLIMUS; TALINOLOL; TETRACYCLINE DERIVATIVE; UNINDEXED DRUG; WARFARIN;

ARTICLE; CRANBERRY JUICE; DIETARY INTAKE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG EXPOSURE; DRUG HALF LIFE; DRUG METABOLISM; DRUG SOLUBILITY; DRUG TRANSPORT; ENZYME INHIBITION; FOLLOW UP; FOOD DRUG INTERACTION; GRAPEFRUIT JUICE; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LEAFY VEGETABLE; MULTIPLE CYCLE TREATMENT; NONHUMAN; ORANGE JUICE; POMEGRANATE JUICE; PRACTICE GUIDELINE; SINGLE DRUG DOSE;

ADMINISTRATION, ORAL; ANIMALS; BIOLOGICAL AVAILABILITY; BIOLOGICAL TRANSPORT; BIOTRANSFORMATION; FOOD-DRUG INTERACTIONS; HUMANS; INTESTINAL ABSORPTION; INTESTINAL MUCOSA; INTESTINES; MEMBRANE TRANSPORT PROTEINS; PHARMACEUTICAL PREPARATIONS; PHARMACOKINETICS; PRODRUGS; RESEARCH DESIGN;

EID: 79851502290     PISSN: 13892002     EISSN: None     Source Type: Journal    
DOI: 10.2174/138920010794328869     Document Type: Article

References (178)

1. Piquette-Miller, M.; Grant, D. M. The art and science of personalized medicine. Clin. Pharmacol. Ther., 2007, 81(3), 311-315. (Pubitemid 46364497)
2. Robertson, G. R.; Grant, D. M.; Piquette-Miller, M. Pharmacogenetics of pharmacoecology: which route to personalized medicine? Clin. Pharmacol. Ther., 2009, 85(4), 343-348.
3. Koster, E. S.; Rodin, A. S.; Raaijmakers, J. A.; Maitland-van der Zee, A. H. Systems biology in pharmacogenomic research: the way to personalized prescribing? Pharmacogenomics, 2009, 10(6), 971-981.
4. Flexner, C., Pharmacoecology: a new name for an old science. Clin. Pharmacol. Ther., 2008, 83(3), 375-379. (Pubitemid 351272646)
5. McLachlan, A. J.; Hilmer, S. N.; Le Couteur, D. G. Variability in response to medicines in older people: phenotypic and genotypic factors. Clin. Pharmacol. Ther., 2009, 85(4), 431-433.
6. Galetin, A.; Gertz, M.; Houston, J. B. Contribution of intestinal cytochrome P450-mediated metabolism to drug-drug inhibition and induction interactions. Drug Metab. Pharmacokinet., 2010, 25(1), 28-47.
7. Shen, D. D.; Kunze, K. L.; Thummel, K. E. Enzyme-catalyzed processes of first-pass hepatic and intestinal drug extraction. Adv. Drug Deliv. Rev., 1997, 27 (2-3), 99-127. (Pubitemid 27417869)
8. Yang, J.; Jamei, M.; Yeo, K. R.; Tucker, G. T.; Rostami-Hodjegan, A. Prediction of intestinal first-pass drug metabolism. Curr. Drug Metab., 2007, 8(7), 676-684. (Pubitemid 47578116)
9. Galetin, A.; Gertz, M.; Houston, J. B. Potential role of intestinal first-pass metabolism in the prediction of drug-drug interactions. Expert Opin. Drug Metab. Toxicol., 2008, 4(7), 909-922.
10. Hisaka, A.; Ohno, Y.; Yamamoto, T.; Suzuki, H. Theoretical considerations on quantitative prediction of drug-drug interactions. Drug Metab. Pharmacokinet., 2010, 25(1), 48-61.
11. Galetin, A.; Hinton, L. K.; Burt, H.; Obach, R. S.; Houston, J. B. Maximal inhibition of intestinal first-pass metabolism as a pragmatic indicator of intestinal contribution to the drug-drug interactions for CYP3A4 cleared drugs. Curr. Drug Metab., 2007, 8(7), 685-693. (Pubitemid 47591312)
12. Fahmi, O. A.; Maurer, T. S.; Kish, M.; Cardenas, E.; Boldt, S.; Nettleton, D. A combined model for predicting CYP3A4 clinical net drug-drug interaction based on CYP3A4 inhibition, inactivation, and induction determined in vitro. Drug Metab. Dispos., 2008, 36(8), 1698-1708.
13. Fahmi, O. A.; Hurst, S.; Plowchalk, D.; Cook, J.; Guo, F.; Youdim, K.; Dickins, M.; Phipps, A.; Darekar, A.; Hyland, R.; Obach, R. S. Comparison of different algorithms for predicting clinical drug-drug interactions, based on the use of CYP3A4 in vitro data: predictions of compounds as precipitants of interaction. Drug Metab. Dispos., 2009, 37(8), 1658-1666.
14. Gertz, M.; Harrison, A.; Houston, J. B.; Galetin, A. Prediction of human intestinal first-pass metabolism of 25 CYP3A substrates from in vitro clearance and permeability data. Drug Metab. Dispos., 2010, 38(7), 1147-1158.
15. Rowland Yeo, K.; Jamei, M.; Yang, J.; Tucker, G. T.; Rostami-Hodjegan, A. Physiologically based mechanistic modelling to predict complex drug-drug interactions involving simultaneous competitive and time-dependent enzyme inhibition by parent compound and its metabolite in both liver and gut - the effect of diltiazem on the time-course of exposure to triazolam. Eur. J. Pharm. Sci., 2010, 39(5), 298-309.
16. Klepser, T. B.; Doucette, W. R.; Horton, M. R.; Buys, L. M.; Ernst, M. E.; Ford, J. K.; Hoehns, J. D.; Kautzman, H. A.; Logemann, C. D.; Swegle, J. M.; Ritho, M.; Klepser, M. E. Assessment of patients' perceptions and beliefs regarding herbal therapies. Pharma-cotherapy, 2000, 20(1), 83-87. (Pubitemid 30036105)
17. Lynch, N.; Berry, D. Differences in perceived risks and benefits of herbal, over-the-counter conventional, and prescribed conventional, medicines, and the implications of this for the safe and effective use of herbal products. Complement. Ther. Med., 2007, 15(2), 84-91. (Pubitemid 46825423)
18. Huang, S. M.; Strong, J. M.; Zhang, L.; Reynolds, K. S.; Nallani, S.; Temple, R.; Abraham, S.; Habet, S. A.; Baweja, R. K.; Burckart, G. J.; Chung, S.; Colangelo, P.; Frucht, D.; Green, M. D.; Hepp, P.; Karnaukhova, E.; Ko, H. S.; Lee, J. I.; Marroum, P. J.; Norden, J. M.; Qiu, W.; Rahman, A.; Sobel, S.; Stifano, T.; Thummel, K.; Wei, X. X.; Yasuda, S.; Zheng, J. H.; Zhao, H.; Lesko, L. J. New era in drug interaction evaluation: US Food and Drug Administration update on CYP enzymes, transporters, and the guidance process. J. Clin. Pharmacol., 2008, 48(6), 662-670. (Pubitemid 351713150)
19. Zhang, L.; Reynolds, K. S.; Zhao, P.; Huang, S. M. Drug interactions evaluation: an integrated part of risk assessment of therapeutics. Toxicol. Appl. Pharmacol., 2010, 243(2), 134-145.
20. Boullata, J. I.; Barber, J. R. A perspective on drug-nutrient interactions. In: Handbook of Drug-Nutrient Interactions; Boullata, J. I., Armenti, V. T., Eds.; Humana: Totowa, 2004; pp. 3-25.
21. Santos, C. A.; Boullata, J. I. An approach to evaluating drug-nutrient interactions. Pharmacotherapy, 2005, 25(12), 1789-1800. (Pubitemid 41790101)
22. Genser, D. Food and drug interaction: consequences for the nutrition/health status. Ann. Nutr. Metab., 2008, 52 (Suppl 1), 29-32. (Pubitemid 351496702)
23. Chan, L. N. Drug-nutrient interaction in clinical nutrition. Curr. Opin. Clin. Nutr. Metab. Care, 2002, 5(3), 327-332.
24. Farkas, D.; Greenblatt, D. J. Influence of fruit juices on drug disposition: discrepancies between in vitro and clinical studies. Expert Opin. Drug Metab. Toxicol., 2008, 4(4), 381-393. (Pubitemid 351728513)
25. Au Yeung, S. C.; Ensom, M. H. Phenytoin and enteral feedings: does evidence support an interaction? Ann. Pharmacother., 2000, 34, 896-905. (Pubitemid 30471273)
26. Polk, R. E. Drug-drug interactions with ciprofloxacin and other fluoroquinolones. Am. J. Med., 1989, 87 5 A), 76S-81S. (Pubitemid 20005151)
27. Neuvonen, P. J. Interactions with the absorption of tetracyclines. Drugs, 1976, 11(1), 45-54.
28. Singh, B. N. Effects of food on clinical pharmacokinetics. Clin. Pharmacokinet., 1999, 37(3), 213-255. (Pubitemid 29452756)
29. Schmidt, L. E.; Dalhoff, K. Food-drug interactions. Drugs, 2002, 62(10), 1481-1502. (Pubitemid 34804156)
30. Fleisher, D.; Li, C.; Zhou, Y.; Pao, L. H.; Karim, A. Drug, meal and formulation interactions influencing drug absorption after oral administration. Clinical implications. Clin. Pharmacokinet., 1999, 36(3), 233-254. (Pubitemid 29178760)
31. Rohde, L. E.; de Assis, M. C.; Rabelo, E. R. Dietary vitamin K intake and anticoagulation in elderly patients. Curr. Opin. Clin. Nutr. Metab. Care, 2007, 10(1), 1-5. (Pubitemid 44913869)
32. Booth, S. L.; Centurelli, M. A. Vitamin K: a practical guide to the dietary management of patients on warfarin. Nutr. Rev., 1999, 57 9 Pt 1), 288-296. (Pubitemid 29514067)
33. Handbook of Drug-Nutrient Interactions, Boullata, J. I., Armenti, V. T., Eds.; Humana: New Jersey, 2004.
34. Nutrition in Pharmacy Practice, Wolinsky, I., Williams, L., Eds.; American Pharmaceutical Association: Washington, DC, 2002.
35. Stargrove, M. B.; Treasure, J.; McKee, D. L. Herb, Nutrient, and Drug Interactions: Clinical Implications and Therapeutic Strategies; Mosby Elsevier: Missouri, 2008.
36. Handbook of Food-Drug Interactions, McCabe, B. J., Frankel, E. H., Wolfe, J. J., Eds.; CRC Press: Florida, 2003.
37. Espin, J. C.; Garcia-Conesa, M. T.; Tomas-Barberan, F. A. Nutraceuticals: facts and fiction. Phytochemistry, 2007, 68 (22-24), 2986-3008. (Pubitemid 350180953)
38. Qato, D. M.; Alexander, G. C.; Conti, R. M.; Johnson, M.; Schumm, P.; Lindau, S. T. Use of prescription and over-the-counter medications and dietary supplements among older adults in the United States. JAMA, 2008, 300(24), 2867-2878.
39. Nahin, R. L.; Pecha, M.; Welmerink, D. B.; Sink, K.; DeKosky, S. T.; Fitzpatrick, A. L. Concomitant use of prescription drugs and dietary supplements in ambulatory elderly people. J. Am. Geriatr. Soc., 2009, 57(7), 1197-1205.
40. Loya, A. M.; Gonzalez-Stuart, A.; Rivera, J. O. Prevalence of polypharmacy, polyherbacy, nutritional supplement use and potential product interactions among older adults living on the United States-Mexico border: a descriptive, questionnaire-based study. Drugs Aging, 2009, 26(5), 423-436.
41. Dresser, G. K.; Bailey, D. G. The effects of fruit juices on drug disposition: a new model for drug interactions. Eur. J. Clin. Invest., 2003, 33 (Suppl 2), 10-16. (Pubitemid 37421611)
42. Lin, J. H.; Lu, A. Y. Interindividual variability in inhibition and induction of cytochrome P450 enzymes. Annu. Rev. Pharmacol. Toxicol., 2001, 41, 535-567. (Pubitemid 32385898)
43. Paine, M. F.; Hart, H. L.; Ludington, S. S.; Haining, R. L.; Rettie, A. E.; Zeldin, D. C. The human intestinal cytochrome P450 "pie". Drug Metab. Dispos., 2006, 34(5), 880-886.
44. Gibbs, M. A.; Hosea, N. A. Factors affecting the clinical development of cytochrome P450 3A substrates. Clin. Pharmacokinet., 2003, 42(11), 969-984. (Pubitemid 37056104)
45. Kim, H.; Yoon, Y. J.; Shon, J. H.; Cha, I. J.; Shin, J. G.; Liu, K. H. Inhibitory effects of fruit juices on CYP3A activity. Drug Metab. Dispos., 2006, 34(4), 521-523.
46. Gertz, M.; Davis, J. D.; Harrison, A.; Houston, J. B.; Galetin, A. Grapefruit juice-drug interaction studies as a method to assess the extent of intestinal availability: utility and limitations. Curr. Drug Metab., 2008, 9(8), 785-795.
47. Huang, S. M.; Lesko, L. J. Drug-drug, drug-dietary supplement, and drug-citrus fruit and other food interactions: what have we learned? J. Clin. Pharmacol., 2004, 44(6), 559-569. (Pubitemid 38668017)
48. Kupferschmidt, H. H.; Ha, H. R.; Ziegler, W. H.; Meier, P. J.; Krahenbuhl, S. Interaction between grapefruit juice and midazolam in humans. Clin. Pharmacol. Ther., 1995, 58(1), 20-28.
49. Saito, M.; Hirata-Koizumi, M.; Matsumoto, M.; Urano, T.; Hasegawa, R. Undesirable effects of citrus juice on the pharmacokinetics of drugs: focus on recent studies. Drug Saf., 2005, 28(8), 677-694. (Pubitemid 41132455)
50. Bailey, D. G.; Spence, J. D.; Munoz, C.; Arnold, J. M. Interaction of citrus juices with felodipine and nifedipine. Lancet, 1991, 337(8736), 268-269.
51. Schmiedlin-Ren, P.; Edwards, D. J.; Fitzsimmons, M. E.; He, K.; Lown, K. S.; Woster, P. M.; Rahman, A.; Thummel, K. E.; Fisher, J. M.; Hollenberg, P. F.; Watkins, P. B. Mechanisms of enhanced oral availability of CYP3A4 substrates by grapefruit constituents. Decreased enterocyte CYP3A4 concentration and mechanism-based inactivation by furanocoumarins. Drug Metab. Dispos., 1997, 25(11), 1228-1233. (Pubitemid 27490665)
52. Lown, K. S.; Bailey, D. G.; Fontana, R. J.; Janardan, S. K.; Adair, C. H.; Fortlage, L. A.; Brown, M. B.; Guo, W.; Watkins, P. B. Grapefruit juice increases felodipine oral availability in humans by decreasing intestinal CYP3A protein expression. J. Clin. Invest., 1997, 99(10), 2545-2553. (Pubitemid 27227734)
53. Paine, M. F.; Widmer, W. W.; Hart, H. L.; Pusek, S. N.; Beavers, K. L.; Criss, A. B.; Brown, S. S.; Thomas, B. F.; Watkins, P. B. A furanocoumarin-free grapefruit juice establishes furanocoumarins as the mediators of the grapefruit juice-felodipine interaction. Am. J. Clin. Nutr., 2006, 83(5), 1097-1105. (Pubitemid 44713110)
54. Bailey, D. G.; Spence, J. D.; Edgar, B.; Bayliff, C. D.; Arnold, J. M. Ethanol enhances the hemodynamic effects of felodipine. Clin. Invest. Med., 1989, 12(6), 357-362. (Pubitemid 20014984)
55. Bailey, D. G.; Arnold, J. M.; Munoz, C.; Spence, J. D. Grapefruit juice-felodipine interaction: mechanism, predictability, and effect of naringin. Clin. Pharmacol. Ther., 1993, 53(6), 637-642. (Pubitemid 23188114)
56. Edwards, D. J.; Bellevue, F. H., 3rd; Woster, P. M. Identification of 6', 7'-dihydroxybergamottin, a cytochrome P450 inhibitor, in grapefruit juice. Drug Metab. Dispos., 1996, 24(12), 1287-1290.
57. He, K.; Iyer, K. R.; Hayes, R. N.; Sinz, M. W.; Woolf, T. F.; Hol-lenberg, P. F. Inactivation of cytochrome P450 3A4 by bergamot-tin, a component of grapefruit juice. Chem. Res. Toxicol., 1998, 11(4), 252-259. (Pubitemid 28194348)
58. Takanaga, H.; Ohnishi, A.; Matsuo, H.; Sawada, Y. Inhibition of vinblastine efflux mediated by P-glycoprotein by grapefruit juice components in Caco-2 cells. Biol. Pharm. Bull., 1998, 21(10), 1062-1066. (Pubitemid 28513983)
59. Dresser, G. K.; Bailey, D. G.; Leake, B. F.; Schwarz, U. I.; Daw-son, P. A.; Freeman, D. J.; Kim, R. B. Fruit juices inhibit organic anion transporting polypeptide-mediated drug uptake to decrease the oral availability of fexofenadine. Clin. Pharmacol. Ther., 2002, 71(1), 11-20. (Pubitemid 34124034)
60. Greenblatt, D. J.; von Moltke, L. L.; Harmatz, J. S.; Chen, G.; Weemhoff, J. L.; Jen, C.; Kelley, C. J.; LeDuc, B. W.; Zinny, M. A. Time course of recovery of cytochrome p450 3A function after single doses of grapefruit juice. Clin. Pharmacol. Ther., 2003, 74(2), 121-129. (Pubitemid 36951809)
61. Bailey, D. G.; Dresser, G. K.; Leake, B. F.; Kim, R. B. Naringin is a major and selective clinical inhibitor of organic anion-transporting polypeptide 1A2 (OATP1A2) in grapefruit juice. Clin. Pharmacol. Ther., 2007, 81(4), 495-502. (Pubitemid 46452308)
62. Gubbins, P. O.; Gurley, B. J.; Williams, D. K.; Penzak, S. R.; McConnell, S. A.; Franks, A. M.; Saccente, M. Examining sex-related differences in enteric itraconazole metabolism in healthy adults using grapefruit juice. Eur. J. Clin. Pharmacol., 2008, 64(3), 293-301.
63. Paine, M. F.; Widmer, W. W.; Pusek, S. N.; Beavers, K. L.; Criss, A. B.; Snyder, J.; Watkins, P. B. Further characterization of a furanocoumarin-free grapefruit juice on drug disposition: studies with cyclosporine. Am. J. Clin. Nutr., 2008, 87(4), 863-871. (Pubitemid 351549230)
64. Strauch, K.; Lutz, U.; Bittner, N.; Lutz, W. K. Dose-response relationship for the pharmacokinetic interaction of grapefruit juice with dextromethorphan investigated by human urinary metabolite profiles. Food. Chem. Toxicol., 2009, 47(8), 1928-1935.
65. Seidegard, J.; Randvall, G.; Nyberg, L.; Borga, O. Grapefruit juice interaction with oral budesonide: equal effect on immediate-release and delayed-release formulations. Pharmazie, 2009, 64(7), 461-465.
66. Ueda, N.; Yoshimura, R.; Umene-Nakano, W.; Ikenouchi-Sugita, A.; Hori, H.; Hayashi, K.; Kodama, Y.; Nakamura, J. Grapefruit juice alters plasma sertraline levels after single ingestion of sertraline in healthy volunteers. World J. Biol. Psychiatry, 2009, 10 4 Pt 3), 832-835.
67. Liu, C.; Shang, Y. F.; Zhang, X. F.; Zhang, X. G.; Wang, B.; Wu, Z.; Liu, X. M.; Yu, L.; Ma, F.; Lv, Y. Co-administration of grapefruit juice increases bioavailability of tacrolimus in liver transplant patients: a prospective study. Eur. J. Clin. Pharmacol., 2009, 65(9), 881-885.
68. Yin, O. Q.; Gallagher, N.; Li, A.; Zhou, W.; Harrell, R.; Schran, H. Effect of grapefruit juice on the pharmacokinetics of nilotinib in healthy participants. J. Clin. Pharmacol., 2010, 50(2), 188-194.
69. van Erp, N. P.; Baker, S. D.; Zandvliet, A. S.; Ploeger, B. A.; den Hollander, M.; Chen, Z.; den Hartigh, J.; Konig-Quartel, J. M.; Guchelaar, H. J.; Gelderblom, H. Marginal increase of sunitinib exposure by grapefruit juice. Cancer Chemother. Pharmacol., (Online early access). DOI 10.1007/s00280-010- 1367-0. Published Online: May 29, 2010. http://www.springerlink.com.libproxy. lib.unc.edu/content/p808760j34663431/fulltext.pdf (accessed July 21, 2010).
70. Nieminen, T. H.; Hagelberg, N. M.; Saari, T. I.; Neuvonen, M.; Neuvonen, P. J.; Laine, K.; Olkkola, K. T. Grapefruit juice enhances the exposure to oral oxycodone. Basic Clin. Pharmacol. Toxicol., 2010, 107(4), 782-788.
71. Tapaninen, T.; Neuvonen, P. J.; Niemi, M. Grapefruit juice greatly reduces the plasma concentrations of the OATP2B1 and CYP3A4 substrate aliskiren. Clin. Pharmacol. Ther., 2010, 88(3), 339-342.
72. Morton, J. F. Fruits of Warm Climates; Florida Flair Books: Florida, 1987.
73. Guo, L. Q.; Fukuda, K.; Ohta, T.; Yamazoe, Y. Role of furano-coumarin derivatives on grapefruit juice-mediated inhibition of human CYP3A activity. Drug Metab. Dispos., 2000, 28(7), 766-771. (Pubitemid 30470826)
74. Egashira, K.; Fukuda, E.; Onga, T.; Yogi, Y.; Matsuya, F.; Koyabu, N.; Ohtani, H.; Sawada, Y. Pomelo-induced increase in the blood level of tacrolimus in a renal transplant patient. Transplantation, 2003, 75(7), 1057. (Pubitemid 36438541)
75. Grenier, J.; Fradette, C.; Morelli, G.; Merritt, G. J.; Vranderick, M.; Ducharme, M. P. Pomelo juice, but not cranberry juice, affects the pharmacokinetics of cyclosporine in humans. Clin. Pharmacol. Ther., 2006, 79(3), 255-262.
76. *3 polymorphism in the fate and action of felodipine. Curr. Drug Metab., 2007, 8(6), 623-630. (Pubitemid 47209099)
77. Al-Ghazawi, M. A.; Tutunji, M. S.; AbuRuz, S. M. The effects of pummelo juice on pharmacokinetics of sildenafil in healthy adult male Jordanian volunteers. Eur. J. Clin. Pharmacol., 2010, 66(2), 159-163.
78. Cote, J.; Caillet, S.; Doyon, G.; Sylvain, J. F.; Lacroix, M. Bioac-tive compounds in cranberries and their biological properties. Crit. Rev. Food Sci. Nutr., 2010, 50(7), 666-679.
79. Pappas, E.; Schaich, K. M. Phytochemicals of cranberries and cranberry products: characterization, potential health effects, and processing stability. Crit. Rev. Food Sci. Nutr., 2009, 49(9), 741-781.
80. Duthie, S. J.; Jenkinson, A. M.; Crozier, A.; Mullen, W.; Pirie, L.; Kyle, J.; Yap, L. S.; Christen, P.; Duthie, G. G. The effects of cranberry juice consumption on antioxidant status and biomarkers relating to heart disease and cancer in healthy human volunteers. Eur. J. Nutr., 2006, 45(2), 113-122. (Pubitemid 43345204)
81. Pérez-López, F. R.; Haya, J.; Chedraui P. Vaccinium macrocarpon: an interesting option for women with recurrent urinary tract infections and other health benefits. J. Obstet. Gynaecol. Res., 2009, 35(4), 630-639.
82. Uesawa, Y.; Mohri, K. Effects of cranberry juice on nifedipine pharmacokinetics in rats. J. Pharm. Pharmacol., 2006, 58(8), 1067-1072. (Pubitemid 44213639)
83. Grenier, J.; Fradette, C.; Morelli, G.; Merritt, G. J.; Vranderick, M.; Ducharme, M. P. Pomelo juice, but not cranberry juice, affects the pharmacokinetics of cyclosporine in humans. Clin. Pharmacol. Ther., 2006, 79(3), 255-262.
84. Lilja, J. J.; Backman, J. T.; Neuvonen, P. J. Effects of daily ingestion of cranberry juice on the pharmacokinetics of warfarin, tizanidine, and midazolam-probes of CYP2C9, CYP1A2, and CYP3A4. Clin. Pharmacol. Ther., 2007, 81(6), 833-839. (Pubitemid 46788294)
85. Ngo, N.; Yan, Z.; Graf, T. N.; Carrizosa, D. R.; Kashuba, A. D.; Dees, E. C.; Oberlies, N. H.; Paine, M. F. Identification of a cranberry juice product that inhibits enteric CYP3A-mediated first-pass metabolism in humans. Drug Metab. Dispos., 2009, 37(3), 514-522.
86. Kim, E.; Sy-Cordero, A.; Graf, T. N.; Brantley, S. J.; Paine, M. F.; Oberlies, N. H. Isolation and identification of intestinal CYP3A inhibitors from cranberry (Vaccinium macrocarpon) using human intestinal microsomes. Planta Med., (Online early access). DOI:10.1055/s-0030-1250259. Published Online: Aug. 17, 2010. http://www.thieme-connect.de/ejournals/toc/plantamedica (accessed Aug. 17, 2010).
87. Mohammed Abdul, M. I.; Jiang, X.; Williams, K. M.; Day, R. O.; Roufogalis, B. D.; Liauw, W. S.; Xu, H.; McLachlan, A. J. Phar-macodynamic interaction of warfarin with cranberry but not with garlic in healthy subjects. Br. J. Pharmacol., 2008, 154(8), 1691-700.
88. Upton, R. In: American Herbal Pharmacopoeia Cranberry Fruit: Vaccinium macrocarpon Aiton: Standards of Analysis, Quality Control, and Therapeutics; American Herbal Pharmacopoeia: California, 2002.
89. Zikria, J.; Goldman, R.; Ansell, J. Cranberry juice and warfarin: when bad publicity trumps science. Am. J. Med., 2010, 123(5), 384-392.
90. Warfarin [package insert]. Princeton (NJ): Bristol-Myers Squibb Company; 2010.
91. Tzulker, R.; Glazer, I.; Bar-Ilan, I.; Holland, D.; Aviram, M.; Amir, R. Antioxidant activity, polyphenol content, and related compounds in different fruit juices and homogenates prepared from 29 different pomegranate accessions. J. Agric. Food Chem., 2007, 55(23), 9559-9570. (Pubitemid 350205310)
92. Hidaka, M.; Okumura, M.; Fujita, K.; Ogikubo, T.; Yamasaki, K.; Iwakiri, T.; Setoguchi, N.; Arimori, K. Effects of pomegranate juice on human cytochrome p450 3A (CYP3A) and carbamazepine pharmacokinetics in rats. Drug Metab. Dispos., 2005, 33(5), 644-648. (Pubitemid 40593878)
93. Farkas, D.; Oleson, L. E.; Zhao, Y.; Harmatz, J. S.; Zinny, M. A.; Court, M. H.; Greenblatt, D. J. Pomegranate juice does not impair clearance of oral or intravenous midazolam, a probe for cytochrome P450-3A activity: comparison with grapefruit juice. J. Clin. Pharmacol., 2007, 47(3), 286-294. (Pubitemid 46294718)
94. Yeo, C.; Shon, J.; Liu, K.; Lee, D.; Yoon, Y.; Shin, J. The effects of pomegranate juice on pharmacokinetics of simvastatin in healthy Korean subjects. Clin. Pharmacol. Ther., 2006, 79(2), 23.
95. Jarvis, S.; Li, C.; Bogle, R. G. Possible interaction between pomegranate juice and warfarin. Emerg. Med. J., 2010, 27(1), 74-75.
96. Komperda, K. E. Potential interaction between pomegranate juice and warfarin. Pharmacotherapy, 2009, 29(8), 1002-1006.
97. Nagata, M.; Hidaka, M.; Sekiya, H.; Kawano, Y.; Yamasaki, K.; Okumura, M.; Arimori, K. Effects of pomegranate juice on human cytochrome P450 2C9 and tolbutamide pharmacokinetics in rats. Drug Metab. Dispos., 2007, 35(2), 302-305. (Pubitemid 46148744)
98. Sorokin, A. V.; Duncan, B.; Panetta, R.; Thompson, P. D. Rhabdomyolysis associated with pomegranate juice consumption. Am. J. Cardiol., 2006, 98(5), 705-706. (Pubitemid 44233475)
99. Hsieh, P. W.; Hung, C. F.; Fang, J. Y. Current prodrug design for drug discovery. Curr. Pharm. Des., 2009, 15(19), 2236-2250.
100. Walker, C. H.; Mackness, M. I. Esterases: problems of identification and classification. Biochem. Pharmacol., 1983, 32(22), 3265-3269. (Pubitemid 14203676)
101. Liederer, B. M.; Borchardt, R. T. Enzymes involved in the bioconversion of ester-based prodrugs. J. Pharm. Sci., 2006, 95(6), 1177-1195. (Pubitemid 43874435)
102. Patchett, A. A. The chemistry of enalapril. Br. J. Clin. Pharmacol., 1984, 18 (Suppl 2), 201S-207S. (Pubitemid 15128833)
103. Sabra, R. Topics in clinical pharmacology: lovastatin. Am. J. Med. Sci., 1988, 296(6), 426-428. (Pubitemid 19034713)
104. Wang, E.; Casciano, C. N.; Clement, R. P.; Johnson, W. W. HMG-CoA reductase inhibitors (statins) characterized as direct inhibitors of P-glycoprotein. Pharm. Res., 2001, 18(6), 800-806. (Pubitemid 32783516)
105. Li, P.; Callery, P. S.; Gan, L. S.; Balani, S. K. Esterase inhibition attribute of grapefruit juice leading to a new drug interaction. Drug Metab. Dispos., 2007, 35(7), 1023-1031. (Pubitemid 46956420)
106. Li, P.; Callery, P. S.; Gan, L. S.; Balani, S. K. Esterase inhibition by grapefruit juice flavonoids leading to a new drug interaction. Drug Metab. Dispos., 2007, 35(7), 1203-1208. (Pubitemid 46956443)
107. Zhang, L.; Zuo, Z.; Lin, G. Intestinal and hepatic glucuronidation of flavonoids. Mol. Pharm., 2007, 4(6), 833-845.
108. Klaassen, C. D.; Boles, J. W. Sulfation and sulfotransferases 5: the importance of 3'-phosphoadenosine 5'-phosphosulfate (PAPS) in the regulation of sulfation. FASEB J., 1997, 11(6), 404-418. (Pubitemid 27259982)
109. Gamage, N.; Barnett, A.; Hempel, N.; Duggleby, R. G.; Windmill, K. F.; Martin, J. L.; McManus, M. E. Human sulfotransferases and their role in chemical metabolism. Toxicol. Sci., 2006, 90(1), 5-22. (Pubitemid 43264722)
110. Coughtrie, M. W.; Johnston, L. E. Interactions between dietary chemicals and human sulfotransferases-molecular mechanisms and clinical significance. Drug Metab. Dispos., 2001, 29 4 Pt 2), 522-528. (Pubitemid 32275528)
111. Morgan, D. J. Clinical pharmacokinetics of beta-agonists. Clin. Pharmacokinet., 1990, 18, 270-294.
112. Nishimuta, H.; Ohtani, H.; Tsujimoto, M.; Ogura, K.; Hiratsuka, A.; Sawada, Y. Inhibitory effects of various beverages on human recombinant sulfotransferase isoforms SULT1A1 and SULT1A3. Biopharm. Drug Dispos., 2007, 28(9), 491-500. (Pubitemid 351200987)
113. Saruwatari, A.; Okamura, S.; Nakajima, Y.; Narukawa, Y.; Takeda, T.; Tamura, H. Pomegranate juice inhibits sulfoconjugation in Caco-2 human colon carcinoma cells. J. Med. Food, 2008, 11(4), 623-628.
114. Huang, S. M.; Zhao, H.; Lee, J. I.; Reynolds, K.; Zhang, L.; Temple, R.; Lesko, L. J. Therapeutic protein-drug interactions and implications for drug development. Clin. Pharmacol. Ther., 2010, 87(4), 497-503.
115. Benet, L. Z. The drug transporter-metabolism alliance: uncovering and defining the interplay. Mol. Pharm., 2009, 6(6), 1631-1643.
116. Wacher, V. J.; Wu, C. Y.; Benet, L. Z. Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: implications for drug delivery and activity in cancer chemotherapy. Mol. Carcinog., 1995, 13(3), 129-134.
117. Nowack, R.; Andrassy, J.; Fischereder, M.; Unger, M. Effects of dietary factors on drug transport and metabolism: the impact on dosage guidelines in transplant patients. Clin. Pharmacol. Ther., 2009, 85(4), 439-443.
118. Dahan, A.; Amidon, G. L. Grapefruit juice and its constituents augment colchicine intestinal absorption: potential hazardous interaction and the role of p-glycoprotein. Pharm. Res., 2009, 26(4), 883-892.
119. Bamburowicz-Klimkowska, M.; Zywiec, K.; Potentas, A.; Szutowski, M. Impact of the changes in P-glycoprotein activity on domperidone pharmacokinetics in rat plasma. Pharmacol. Rep., 2007, 59(6), 752-756. (Pubitemid 351586568)
120. Becquemont, L.; Verstuyft, C.; Kerb, R.; Brinkmann, U.; Lebot, M.; Jaillon, P.; Funck-Brentano, C. Effect of grapefruit juice on digoxin pharmacokinetics in humans. Clin. Pharmacol. Ther., 2001, 70(4), 311-316. (Pubitemid 33022471)
121. Schwarz, U. I.; Seemann, D.; Oertel, R.; Miehlke, S.; Kuhlisch, E.; Fromm, M. F.; Kim, R. B.; Bailey, D. G.; Kirch, W. Grapefruit juice ingestion significantly reduces talinolol bioavailability. Clin. Pharmacol. Ther., 2005, 77(4), 291-301. (Pubitemid 40470385)
122. Lilja, J. J.; Backman, J. T.; Laitila, J.; Luurila, H.; Neuvonen, P. J. Itraconazole increases but grapefruit juice greatly decreases plasma concentrations of celiprolol. Clin. Pharmacol. Ther., 2003, 73(3), 192-198. (Pubitemid 36269670)
123. Koitabashi, Y.; Kumai, T.; Matsumoto, N.; Watanabe, M.; Sekine, S.; Yanagida, Y.; Kobayashi, S. Orange juice increased the bioavailability of pravastatin, 3-hydroxy-3-methylglutaryl CoA reductase inhibitor, in rats and healthy human subjects. Life Sci., 2006, 78(24), 2852-2859.
124. Matsushima, S.; Maeda, K.; Kondo, C.; Hirano, M.; Sasaki, M.; Suzuki, H.; Sugiyama, Y. Identification of the hepatic efflux transporters of organic anions using double-transfected Madin-Darby canine kidney II cells expressing human organic anion-transporting polypeptide 1B1 (OATP1B1)/multidrug resistance-associated protein 2, OATP1B1/multidrug resistance 1, and OATP1B1/breast cancer resistance protein. J. Pharmacol. Exp. Ther., 2005, 314(3), 1059-1067. (Pubitemid 41205969)
125. Honda, Y.; Ushigome, F.; Koyabu, N.; Morimoto, S.; Shoyama, Y.; Uchiumi, T.; Kuwano, M.; Ohtani, H.; Sawada, Y. Effects of grapefruit juice and orange juice components on P-glycoprotein-and MRP2-mediated drug efflux. Br. J. Pharmacol., 2004, 143(7), 856-864. (Pubitemid 39664844)
126. Takanaga, H.; Ohnishi, A.; Yamada, S.; Matsuo, H.; Morimoto, S.; Shoyama, Y.; Ohtani, H.; Sawada, Y. Polymethoxylated flavones in orange juice are inhibitors of P-glycoprotein but not cytochrome P450 3A4. J. Pharmacol. Exp. Ther., 2000, 293(1), 230-236. (Pubitemid 30180944)
127. Kim, R. B. Organic anion-transporting polypeptide (OATP) transporter family and drug disposition. Eur. J. Clin. Invest., 2003, 33 (Suppl 2), 1-5.
128. Kalliokoski, A.; Niemi, M. Impact of OATP transporters on phar-macokinetics. Br. J. Pharmacol., 2009, 158(3), 693-705.
129. Hagenbuch, B.; Gui, C. Xenobiotic transporters of the human organic anion transporting polypeptides (OATP) family. Xenobiotica, 2008, 38 (7-8), 778-801.
130. Hilgendorf, C.; Ahlin, G.; Seithel, A.; Artursson, P.; Ungell, A. L.; Karlsson, J. Expression of thirty-six drug transporter genes in human intestine, liver, kidney, and organotypic cell lines. Drug Metab. Dispos., 2007, 35(8), 1333-1340. (Pubitemid 47121774)
131. Banfield, C.; Gupta, S.; Marino, M.; Lim, J.; Affrime, M. Grapefruit juice reduces the oral bioavailability of fexofenadine but not desloratadine. Clin. Pharmacokinet., 2002, 41(4), 311-318. (Pubitemid 34533758)
132. Dresser, G. K.; Kim, R. B.; Bailey, D. G. Effect of grapefruit juice volume on the reduction of fexofenadine bioavailability: possible role of organic anion transporting polypeptides. Clin. Pharmacol. Ther., 2005, 77(3), 170-177. (Pubitemid 40269132)
133. Glaeser, H.; Bailey, D. G.; Dresser, G. K.; Gregor, J. C.; Schwarz, U. I.; McGrath, J. S.; Jolicoeur, E.; Lee, W.; Leake, B. F.; Tirona, R. G.; Kim, R. B. Intestinal drug transporter expression and the impact of grapefruit juice in humans. Clin. Pharmacol. Ther., 2007, 81(3), 362-370. (Pubitemid 46364477)
134. Satoh, H.; Yamashita, F.; Tsujimoto, M.; Murakami, H.; Koyabu, N.; Ohtani, H.; Sawada, Y. Citrus juices inhibit the function of human organic anion-transporting polypeptide OATP-B. Drug Metab. Dispos., 2005, 33(4), 518-523. (Pubitemid 40393194)
135. ® [package insert]. Bridgewater (NJ): sanofi-aventis U. S. LLC; 2006.
136. Lilja, J. J.; Raaska, K.; Neuvonen, P. J. Effects of grapefruit juice on the pharmacokinetics of acebutolol. Br. J. Clin. Pharmacol., 2005, 60(6), 659-663. (Pubitemid 41705387)
137. Reif, S.; Nicolson, M. C.; Bisset, D.; Reid, M.; Kloft, C.; Jaehde, U.; McLeod, H. L. Effect of grapefruit juice intake on etoposide bioavailability. Eur. J. Clin. Pharmacol., 2002, 58(7), 491-494. (Pubitemid 35244924)
138. Lilja, J. J.; Laitinen, K.; Neuvonen, P. J. Effects of grapefruit juice on the absorption of levothyroxine. Br. J. Clin. Pharmacol., 2005, 60(3), 337-341. (Pubitemid 41224144)
139. Greenblatt, D. J. Analysis of drug interactions involving fruit beverages and organic anion-transporting polypeptides. J. Clin. Pharmacol., 2009, 49(12), 1403-1407.
140. Bailey, D. G. Fruit juice inhibition of uptake transport: a new type of food-drug interaction. Br. J. Clin. Pharmacol., 2010, 70(5), 645-655.
141. Shirasaka, Y.; Kuraoka, E.; Spahn-Langguth, H.; Nakanishi, T.; Langguth, P.; Tamai, I. Species difference in the effect of grapefruit juice on intestinal absorption of talinolol between human and rat. J. Pharmacol. Exp. Ther., 2010, 332(1), 181-189.
142. Nozawa, T.; Imai, K.; Nezu, J.; Tsuji, A.; Tamai, I. Functional characterization of pH-sensitive organic anion transporting polypeptide OATP-B in human. J. Pharmacol. Exp. Ther., 2004, 308(2), 438-45. (Pubitemid 38134202)
143. Mougey, E. B.; Feng, H.; Castro, M.; Irvin, C. G.; Lima, J. J. Absorption of montelukast is transporter mediated: a common variant of OATP2B1 is associated with reduced plasma concentrations and poor response. Pharmacogenet. Genomics., 2009, 19(2), 129-138.
144. Yee, G. C.; Stanley, D. L.; Pessa, L. J.; Dalla Costa, T.; Beltz, S. E.; Ruiz, J.; Lowenthal, D. T. Effect of grapefruit juice on blood cyclosporin concentration. Lancet, 1995, 345, 955-956.
145. Lilja, J. J.; Raaska, K.; Neuvonen, P. J. Effects of orange juice on the pharmacokinetics of atenolol. Eur. J. Clin. Pharmacol., 2005, 61 (5-6), 337-340. (Pubitemid 41569306)
146. Lilja, J. J.; Juntti-Patinen, L.; Neuvonen, P. J. Orange juice
147. Neuhofel, A. L.; Wilton, J. H.; Victory, J. M.; Hejmanowsk, L. G.; Amsden, G. W. Lack of bioequivalence of ciprofloxacin when administered with calcium-fortified orange juice: a new twist on an old interaction. J. Clin. Pharmacol., 2002, 42(4), 461-466. (Pubitemid 34259781)
148. Wallace, A. W.; Victory, J. M.; Amsden, G. W. Lack of bioequivalence when levofloxacin and calcium-fortified orange juice are coadministered to healthy volunteers. J. Clin. Pharmacol., 2003, 43(5), 539-544. (Pubitemid 36506155)
149. Maeda, T.; Takahashi, K.; Ohtsu, N.; Oguma, T.; Ohnishi, T.; Atsumi, R.; Tamai, I. Identification of influx transporter for the quinolone antibacterial agent levofloxacin. Mol. Pharm., 2007, 4(1), 85-94.
150. Kato, Y.; Miyazaki, T.; Kano, T.; Sugiura, T.; Kubo, Y.; Tsuji, A. Involvement of influx and efflux transport systems in gastrointestinal absorption of celiprolol. J. Pharm. Sci., 2009, 98(7), 2529-2539.
151. Uesawa, Y.; Mohri, K. Hesperidin in orange juice reduces the absorption of celiprolol in rats. Biopharm. Drug Dispos., 2008, 29(3), 185-188. (Pubitemid 351722163)
152. Mandery, K.; Bujok, K.; Schmidt, I.; Keiser, M.; Siegmund, W.; Balk, B.; König, J.; Fromm, M. F.; Glaeser, H. Influence of the fla-vonoids apigenin, kaempferol, and quercetin on the function of organic anion transporting polypeptides 1A2 and 2B1. Biochem. Pharmacol., 2010, 80(11), 1746-1753.
153. Gerhauser, C. Cancer chemopreventive potential of apples, apple juice, and apple components. Planta Med., 2008, 74(13), 1608-1624.
154. Paine, M. F.; Oberlies, N. H. Clinical relevance of the small intestine as an organ of drug elimination: drug-fruit juice interactions. Expert Opin. Drug Metab. Toxicol., 2007, 3(1), 67-80. (Pubitemid 47307455)
155. De Castro, W. V.; Mertens-Talcott, S.; Rubner, A.; Butterweck, V.; Derendorf, H. Variation of flavonoids and furanocoumarins in grapefruit juices: a potential source of variability in grapefruit juice-drug interaction studies. J. Agric. Food Chem., 2006, 54(1), 249-255. (Pubitemid 43119947)
156. Smillie, T. J.; Khan, I. A. A comprehensive approach to identifying and authenticating botanical products. Clin. Pharmacol. Ther., 2010, 87(2), 175-186.
157. Fenneteau, F.; Poulin, P.; Nekka, F. Physiologically based predictions of the impact of inhibition of intestinal and hepatic metabolism on human pharmacokinetics of CYP3A substrates. J. Pharm. Sci., 2010, 99(1), 486-514.
158. Johnson, W. W. Cytochrome P450 inactivation by pharmaceuticals and phytochemicals: therapeutic relevance. Drug Metab. Rev., 2008, 40(1), 101-147. (Pubitemid 351220647)
159. Iwanaga, K.; Hayashi, M.; Hamahata, Y.; Miyazaki, M.; Shibano, M.; Taniguchi, M.; Baba, K.; Kakemi, M. Furanocoumarin derivatives in Kampo extract medicines inhibit cytochrome P450 3A4 and P-glycoprotein. Drug Metab. Dispos., 2008, 38(8), 1286-1294.
160. Mertens-Talcott, S. U.; Zadezensky, I.; De Castro, W. V.; Derendorf, H.; Butterweck, V. Grapefruit-drug interactions: can interactions with drugs be avoided? J. Clin. Pharmacol., 2006, 46(12), 1390-1416. (Pubitemid 44704201)
161. http://forum.opiophile.org (accessed June 20, 2010).
162. http://www.drugs-forum.com/forum/forumdisplay.php?f=33 (accessed June 20, 2010).
163. Smith, N. F.; Baker, S. D.; Gonzalez, F. J.; Harris, J. W.; Figg, W. D.; Sparreboom, A. Modulation of erlotinib pharmacokinetics in mice by a novel cytochrome P450 3A4 inhibitor, BAS 100. Br. J. Cancer, 2008, 98(10), 1630-1632. (Pubitemid 351684683)
164. thAnnual Meeting of the American Association for Cancer Research, Denver, CO, Apr. 18-22 2009; AACR: Philadelphia, 2009; LB-135.
165. Ratain, M. J.; Cohen, E. E. The value meal: how to save $1, 700 per month or more on lapatinib. J. Clin. Oncol., 2007, 25(23), 3397-3398. (Pubitemid 47310874)
166. Ioannides-Demos, L. L.; Christophidis, N.; Ryan, P.; Angelis, P.; Liolios, L.; McLean, A. J. Dosing implications of a clinical interaction between grapefruit juice and cyclosporine and metabolite concentrations in patients with autoimmune diseases. J. Rheumatol., 1997, 24(1), 49-54. (Pubitemid 27059857)
167. Rapamycin With Grapefruit Juice for Advanced Malignancies. http://clinicaltrials.gov/ct2/show/NCT00375245 (accessed June 21, 2010).
168. McMains, V. Grapefruit Juice Shows Promise in Some Cancer Treatments. Chicago Tribune [Online] Aug. 5, 2009. http://articles.chicagotribune.com/2009- 08-05/news/0908050065-1-grapefruit-juice-cancer-treatments-lymph (accessed June 21, 2010).
169. http://www.news-medical.net/news/2009/04/20/48569.aspx (accessed June 20, 2010).
170. Watkins, P. B. The role of cytochromes P-450 in cyclosporine metabolism. J. Am. Acad. Dermatol., 1990, 23(6), 301-311.
171. Ducharme, M. P.; Provenzano, R.; Dehoorne-Smith, M.; Edwards, D. J. Trough concentrations of cyclosporine in blood following administration with grapefruit juice. Br. J. Clin. Pharmacol., 1993, 36(5), 457-459. (Pubitemid 23344156)
172. Dahan, A.; Altman, H. Food-drug interaction: grapefruit juice augments drug bioavailability-mechanism, extent and relevance. Eur. J. Clin. Nutr., 2004, 58(1), 1-9. (Pubitemid 38159306)
173. Liu, C.; Shang, Y. F.; Zhang, X. F.; Zhang, X. G.; Wang, B.; Wu, Z.; Liu, X. M.; Yu, L.; Ma, F.; Lv, Y. Co-administration of grapefruit juice increases bioavailability of tacrolimus in liver transplant patients: a prospective study. Eur. J. Clin. Pharmacol., 2009, 65(9), 881-885.
174. Tsourounis, C.; Bent, S. Why change is needed in research examining dietary supplements. Clin. Pharmacol. Ther., 2010, 87(2), 147-149.
175. U. S. Food and Drug Administration. Guidance for Industry: Botanical Drug Products. http://www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInforma-tion/Guidances/ucm070491.pdf (accessed Aug. 1, 2010).
176. Schilter, B.; Andersson, C.; Anton, R.; Constable, A.; Kleiner, J.; O'Brien, J.; Renwick, A. G.; Korver, O.; Smit, F.; Walker, R. Guidance for the safety assessment of botanicals and botanical preparations for use in food and food supplements. Food Chem. Toxicol., 2003, 41(12), 1625-1649. (Pubitemid 37249332)
177. Speijers, G.; Bottex, B.; Dusemund, B.; Lugasi, A.; Tóth, J.; Am-berg-Müller, J.; Galli, C. L.; Silano, V.; Rietjens, I. M. Safety assessment of botanicals and botanical preparations used as ingredients in food supplements: testing an European Food Safety Authority-tiered approach. Mol. Nutr. Food Res., 2010, 54(2), 175-185.
178. Dentali, S. J. Successful botanical research requires botanical expertise. Clin. Pharmacol. Ther., 2010, 87(2), 149-151.